Share This

Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
《大行》大摩降國藥目標價至28元 評級「增持」

2024-04-19T  
中國生物製藥創新藥羅伐昔替尼片關鍵註冊研究達主要終點

2024-04-19T  
白雲山新研發非化學原理藥獲國家藥監局批准上市

2024-04-18T  
《大行》瑞銀首予上海醫藥「買入」評級 目標價14.9元

2024-04-17T  
《港股》恆指半日跌320點 科技、汽車及內房股下滑

2024-04-16T  
《大行》匯豐研究微降中生製藥目標價至4.5元 新藥上市和業務前景可觀支持可持續增長

2024-04-16T  
中生製藥受託人購買500萬股 涉1,340.3萬元

2024-04-15T  
歐盟傳最早4月對中國醫療器械採購啟動調查 或影響中資投標

2024-04-15T  
《大行》匯豐研究微降上海醫藥目標價至26.4元 注視今年盈利復甦

2024-04-11T  
中生製藥治療突變非小細胞肺癌藥物顯示較高腫瘤緩解率

2024-04-11T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.